Verified Panel · Burden Studies · Treatment Switching
Research across the
full evidence lifecycle
Rare hematologic disorders present a distinct set of research challenges: lifelong disease management, treatment regimens that range from prophylactic infusions to gene therapy, and patient populations whose disease severity can vary dramatically even within the same diagnosis.
MedPanel brings verified patient, caregiver, and physician panels to bear on this complexity, supporting sponsors across the full evidence lifecycle — from early disease understanding through post-launch real-world research.
Treatment burden · Severity spectrum · Evolving care
N. America · Europe · Asia-Pacific · LATAM
Attestation · Medical record · Screening
Patient, caregiver & physician
Research Challenges Specific to Rare Hematologic Disorders
Two structural realities — hard-to-capture treatment burden across a wide severity spectrum, and a rapidly evolving treatment landscape — shape how research in this area must be designed.
- Treatment burden is hard to capture, and severity varies within a diagnosis. Rare hematologic conditions frequently involve a treatment burden that is difficult to capture through standard quality-of-life instruments alone. Regular infusion schedules, bleeding or clotting risk management, and the logistical demands of maintaining treatment adherence around work, school, and travel all shape patient experience in ways that generic burden-of-illness frameworks can understate. Many of these conditions also span a wide severity spectrum within a single diagnostic label, meaning research design must account for meaningful subgroup variation rather than treating the diagnosis as a single homogeneous population.
- Treatment landscape evolution adds further complexity. Several rare hematologic disorders have seen rapid therapeutic innovation in recent years — extended half-life products, non-factor therapies, and gene therapy approaches entering a treatment paradigm that had been comparatively stable for decades. Research conducted even eighteen months apart can reflect meaningfully different patient and physician mindsets as the standard of care shifts.
Research Approaches MedPanel Applies in This Therapeutic Area
MedPanel matches methodology to the specific research question, spanning burden-of-illness, caregiver, treatment-switching, and label-comprehension research designs.
Burden-of-illness studies
Burden-of-illness studies quantify the treatment, financial, and quality-of-life impact of rare hematologic conditions, capturing both the disease burden itself and the burden imposed by current management regimens — a distinction that matters for therapies positioned around reducing treatment burden rather than only addressing clinical endpoints. MedPanel’s burden studies methodology is built to capture this dual dimension.
Caregiver research
Caregiver research is particularly relevant for pediatric-onset hematologic conditions, where caregivers manage complex treatment schedules, monitor for acute complications, and navigate school and activity accommodations. MedPanel’s caregiver studies practice applies condition-specific burden frameworks suited to this population.
Treatment switching and adherence research
Treatment switching and adherence research helps sponsors understand what drives patients and physicians to move between treatment options as new therapies enter the market — critical intelligence for both commercial forecasting and patient support program design.
Label comprehension and patient education testing
Label comprehension and patient education testing supports new therapy launches, particularly for novel modalities such as gene therapy, where patient and caregiver understanding of long-term monitoring requirements and risk profiles carries particular regulatory and clinical importance. MedPanel’s focus group methodology is frequently applied here, alongside structured survey research for broader validation.
A Verified Panel for a Well-Networked Patient Community
Active advocacy networks and shared terminology make self-reported panels especially vulnerable to misclassification — so verification matters acutely here.
Rare hematologic disorder communities are often well-organized, with active patient advocacy organizations and strong peer networks — which makes self-reported research panels particularly vulnerable to misclassification, since individuals adjacent to the community may be aware enough of terminology and treatment names to misrepresent their own diagnostic status convincingly.
MedPanel’s verification protocol — physician attestation, medical record confirmation, and condition-specific screening — addresses this risk directly. Combined with global reach across North America, Europe, Asia-Pacific, and Latin America, MedPanel can support both single-market and multinational research programs in rare hematologic disorders, including studies that require comparison across healthcare systems with materially different treatment access and reimbursement environments.
Start your research
Start Your Rare Hematologic Disorders Research Program
Whether you need to understand current treatment burden, test materials ahead of a new therapy launch, or build a longitudinal picture of real-world treatment durability, MedPanel’s verified panel and rare disease research specialists are ready to scope your study.
Panel feasibility confirmed for your target population
Methodology outlined for your study goals
Dual burden capture — disease and treatment regimen
Verification: attestation, medical record & screening
Contact MedPanel to discuss your research objectives in rare hematologic disorders. We will confirm panel feasibility for your target population and outline a methodology suited to your study goals.